Please use this identifier to cite or link to this item:
http://hdl.handle.net/123456789/1735| Title: | Heparanase inhibitors in cancer progression: Recent advances |
| Authors: | Kaur R Deb P K Diwan V Saini B |
| Keywords: | AS1411 Heparanase inhibitors M402 PG545 PI-88 SST0001 Suramin. |
| Issue Date: | 2021 |
| Publisher: | Current Pharmaceutical Design |
| Abstract: | Background: An endo-?-glucuronidase enzyme, Heparanase (HPSE), degrades the side chains of polymeric heparan sulfate (HS), a glycosaminoglycan formed by alternate repetitive units of D-glucosamine and D-glucuronic acid/L-iduronic acid. HS is a major component of the extracellular matrix and basement membranes and has been implicated in processes of the tissue's integrity and functional state. The degradation of HS by HPSE enzyme leads to conditions like inflammation, angiogenesis, and metastasis. An elevated HPSE expression with a poor prognosis and its multiple roles in tumor growth and metastasis has attracted significant interest for its inhibition as a potential anti-neoplastic target. |
| URI: | 10.2174/1381612826666201113105250 http://hdl.handle.net/123456789/1735 |
| Appears in Collections: | Journals |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.